Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
SAN DIEGO, May 3, 2022 (GLOBE NEWSWIRE) - Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SAN DIEGO, May 3, 2022 (GLOBE NEWSWIRE) - Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT. A live webcast of the presentation will be available, along with an archived replay accessible for 30 days post-event.
Travere Therapeutics focuses on developing therapies for patients with rare diseases, emphasizing the need for urgent treatment options and collaboration with the rare disease community.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +0.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT.
A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@travere.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.